New viruses for cancer therapy: Meeting clinical needs

Tanner S. Miest, Roberto Cattaneo

Research output: Contribution to journalReview article

161 Scopus citations

Abstract

Early-stage clinical trials of oncolytic virotherapy have reported the safety of several virus platforms, and viruses from three families have progressed to advanced efficacy trials. In addition, preclinical studies have established proof-of-principle for many new genetic engineering strategies. Thus, the virotherapy field now has available a diverse collection of viruses that are equipped to address unmet clinical needs owing to improved systemic administration, greater tumour specificity and enhanced oncolytic efficacy. The current key challenge for the field is to develop viruses that replicate with greater efficiency within tumours while achieving therapeutic synergy with currently available treatments.

Original languageEnglish (US)
Pages (from-to)23-34
Number of pages12
JournalNature Reviews Microbiology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Microbiology(all)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'New viruses for cancer therapy: Meeting clinical needs'. Together they form a unique fingerprint.

  • Cite this